Patients who received Mircera (at a dose calculated using the recommended conversion factor) had a mean change in hemoglobin concentration from baseline of -0.15g/dL (95% CI -0.49, 0.2).

A day after celebrating a patent victory over Roche’s Mircera, Amgen came back down to earth by revealing a sharp decline in earnings due in part to lower sales of its own anaemia drugs in the third ...

The above chart shows that in 4Q15, the revenue from Aranesp is expected to reach about $492.0 million. This is a YoY (year-over-year) rise of 2.7% compared to the drug’s sales in fiscal 4Q14 ...

WASHINGTON, Sept 15 (Reuters) - A federal court let stand a ban on the U.S. sale of Roche Holding AG's Mircera, a rival to Amgen's blockbuster anemia drugs. The U.S. Court of Appeals for the ...

Amgen said that Roche’s drug Mircera (methoxy polyethylene glycol-epoetin beta) infringed on its patents for the drugs Aranesp (darbepoetin alfa) and Epogen (epoetin alfa). Mircera is on the ...